Cellectis Sa Stock Fundamentals
| CMVLF Stock | USD 1.25 0.00 0.00% |
Cellectis SA fundamentals help investors to digest information that contributes to Cellectis' financial success or failures. It also enables traders to predict the movement of Cellectis Pink Sheet. The fundamental analysis module provides a way to measure Cellectis' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Cellectis pink sheet.
Cellectis |
Cellectis SA Company Current Valuation Analysis
Cellectis' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Cellectis Current Valuation | 82.79 M |
Most of Cellectis' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Cellectis SA is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Cellectis SA has a Current Valuation of 82.79 M. This is 99.42% lower than that of the Healthcare sector and 98.22% lower than that of the Biotechnology industry. The current valuation for all United States stocks is 99.5% higher than that of the company.
Cellectis SA Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Cellectis's current stock value. Our valuation model uses many indicators to compare Cellectis value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Cellectis competition to find correlations between indicators driving Cellectis's intrinsic value. More Info.Cellectis SA is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Cellectis' earnings, one of the primary drivers of an investment's value.Cellectis Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cellectis' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Cellectis could also be used in its relative valuation, which is a method of valuing Cellectis by comparing valuation metrics of similar companies.Cellectis is currently under evaluation in current valuation category among its peers.
Cellectis Fundamentals
| Return On Equity | -0.56 | |||
| Return On Asset | -0.24 | |||
| Operating Margin | (6.01) % | |||
| Current Valuation | 82.79 M | |||
| Shares Outstanding | 55.59 M | |||
| Shares Owned By Institutions | 9.80 % | |||
| Price To Earning | (13.64) X | |||
| Price To Book | 0.79 X | |||
| Price To Sales | 4.79 X | |||
| Revenue | 57.29 M | |||
| Gross Profit | 34.18 M | |||
| EBITDA | (103.2 M) | |||
| Net Income | (114.2 M) | |||
| Cash And Equivalents | 153.13 M | |||
| Cash Per Share | 3.37 X | |||
| Total Debt | 18.77 M | |||
| Debt To Equity | 0.52 % | |||
| Current Ratio | 3.17 X | |||
| Book Value Per Share | 3.00 X | |||
| Cash Flow From Operations | (104.56 M) | |||
| Earnings Per Share | (2.95) X | |||
| Number Of Employees | 294 | |||
| Beta | 2.0 | |||
| Market Capitalization | 131.39 M | |||
| Total Asset | 382.08 M | |||
| Retained Earnings | (206 M) | |||
| Working Capital | 239 M | |||
| Current Asset | 297 M | |||
| Current Liabilities | 58 M | |||
| Z Score | 4.2 | |||
| Net Asset | 382.08 M |
About Cellectis Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cellectis SA's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cellectis using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cellectis SA based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France. Cellectis Romainvil operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 294 people.
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in Cellectis Pink Sheet
When determining whether Cellectis SA is a strong investment it is important to analyze Cellectis' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Cellectis' future performance. For an informed investment choice regarding Cellectis Pink Sheet, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cellectis SA. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.